Jnana Therapeutics to Present New Scientific Data and Disclose Chemical Structure of JNT-517 at American Chemical Society Fall 2023 Meeting
BOSTON, August 11, 2023 – Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, today announced that the Company will present the chemical structure of JNT-517, a clinical candidate for the treatment of phenylketonuria (PKU), as well as new data on its discovery and characterization at the American Chemical Society (ACS) Fall 2023 national meeting. The meeting will be held in San Francisco from August 13-17, 2023.
Jnana is advancing JNT-517, an allosteric small molecule inhibitor of the phenylalanine (Phe) transporter SLC6A19, in Phase 1b clinical development as a potential first-in-class oral treatment for PKU.
The Company’s oral presentation in the First Time Disclosures session at ACS Fall 2023 will discuss:
- The discovery effort using Jnana’s RAPID chemoproteomics platform, which led to small molecules that inhibited SLC6A19 through a cryptic allosteric site
- Demonstration of in vivo activity in the Pahenu2 mouse model of classical PKU
- How this work led to the identification of JNT-517, as well as the chemical structure of the clinical candidate
Session: First Time Disclosures I
Title: Discovery and characterization of JNT-517, an inhibitor of SLC6A19 for the treatment of phenylketonuria
Presenter: Dean Brown, Ph.D., Senior Vice President, Head of Discovery Sciences, Jnana Therapeutics
Location: Room 4, South Bldg. (Moscone Center)
Day: Wednesday, August 16, 2023
Time:9:50 a.m. PT
Additional information on ACS Fall 2023 can be found here.
JNT-517 is a selective small molecule inhibitor of the phenylalanine transporter SLC6A19 that has the potential to be a first-in-class oral therapy used to treat any person with PKU, regardless of age or genotype. JNT-517 acts at a novel, cryptic allosteric site to block kidney reabsorption of Phe and offers a promising new approach to reduce blood Phe levels. The U.S. Food and Drug Administration granted JNT-517 Rare Pediatric Disease Designation in late 2022.
About Jnana Therapeutics
Jnana Therapeutics is a clinical-stage biotechnology company leveraging its next-generation RAPID chemoproteomics platform to discover medicines for highly validated, challenging-to-drug targets to treat diseases with high unmet needs. Jnana is focused on developing first- and best-in-class therapies to treat a wide range of diseases, including rare diseases, immune-mediated diseases, and cancer. Jnana’s wholly owned lead program, JNT-517, which targets an allosteric site on the phenylalanine transporter SLC6A19, is a potential first-in-class oral approach for the treatment of phenylketonuria (PKU), a rare genetic metabolic disease. Located in Boston, Jnana brings together scientific leaders in small molecule drug discovery and development, a highly experienced management team, and the backing of leading life science investors Bain Capital Life Sciences, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures, and AbbVie Ventures. For more information, please visit www.jnanatx.com and follow us on Twitter and LinkedIn.